NeuroDerm Ltd. (NASDAQ:NDRM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Neuroderm Ltd. is a clinical-stage pharmaceutical company. It is developing next-generation treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson’s disease (PD). Its product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. NeuroDerm Ltd. is headquartered in Rehovot, Israel. “

Separately, Jefferies Group upped their target price on NeuroDerm from $28.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, September 6th.

Shares of NeuroDerm (NASDAQ:NDRM) opened at 17.55 on Wednesday. The company’s market cap is $380.91 million. The company has a 50-day moving average price of $18.02 and a 200-day moving average price of $17.42. NeuroDerm has a 12-month low of $11.76 and a 12-month high of $20.52.

NeuroDerm (NASDAQ:NDRM) last released its earnings results on Thursday, August 25th. The company reported ($0.32) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.32). On average, analysts predict that NeuroDerm will post ($1.49) earnings per share for the current year.

Hedge funds have recently made changes to their positions in the company. ProShare Advisors LLC increased its stake in shares of NeuroDerm by 1.1% in the second quarter. ProShare Advisors LLC now owns 16,119 shares of the company’s stock valued at $262,000 after buying an additional 173 shares in the last quarter. Northern Trust Corp increased its position in NeuroDerm by 8.2% in the third quarter. Northern Trust Corp now owns 29,570 shares of the company’s stock valued at $547,000 after buying an additional 2,235 shares in the last quarter. Alps Advisors Inc. increased its position in NeuroDerm by 25.6% in the second quarter. Alps Advisors Inc. now owns 30,412 shares of the company’s stock valued at $494,000 after buying an additional 6,192 shares in the last quarter. Swiss National Bank increased its position in NeuroDerm by 50.0% in the second quarter. Swiss National Bank now owns 22,800 shares of the company’s stock valued at $371,000 after buying an additional 7,600 shares in the last quarter. Finally, BlackRock Fund Advisors increased its position in NeuroDerm by 4.0% in the third quarter. BlackRock Fund Advisors now owns 353,080 shares of the company’s stock valued at $6,528,000 after buying an additional 13,685 shares in the last quarter. Institutional investors and hedge funds own 42.77% of the company’s stock.

About NeuroDerm

NeuroDerm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa/carbidopa (LD/CD) or apomorphine concentrations and dosages.

5 Day Chart for NASDAQ:NDRM

Receive News & Stock Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related stocks with our FREE daily email newsletter.